Abstract:
A method is disclosed comprising applying a reversal agent, such as urea, to a formalin fixed tissue sample in order to reverse the effects of the fixation process. An ambient ionisation ion source such as a desorption electrospray ionisation ("DESI") ion source is used to generate analyte or analyte ions from multiple regions of the modified target so that an ion image of the modified target may be generated.
Abstract:
An apparatus for mass spectrometry and/or ion mobility spectrometry is disclosed comprising a first device (31) arranged and adapted to generate aerosol, smoke or vapour from a target and one or more second devices (34,35) arranged and adapted to aspirate aerosol, smoke, vapour and/or liquid to or towards an analyser (33). A liquid trap or separator (32) is provided to capture and/or discard liquid aspirated by the one or more second devices (34,35).
Abstract:
An apparatus for performing ambient ionisation mass and/or ion mobility spectrometry is disclosed. The apparatus comprises a substantially cylindrical, tubular, rod-shaped,coil- shaped, helical or spiral-shaped collision assembly; and a first device arranged and adapted to direct analyte, smoke, fumes, liquid, gas, surgical smoke, aerosol or vapour onto said collision assembly.
Abstract:
Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
Abstract:
The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject based on determining the amounts of at least three biomarkers. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.
Abstract:
Biomarkers relating to de novo lipogenesis are provided, as well as methods for using such biomarkers in an Index to assess DNL. In addition, methods for diagnosing, determining predisposition to, and monitoring progression/regression of diseases related to DNL are provided. Also provided are methods of monitoring the efficacy of treatments for diseases related to DNL as well as other methods based on biomarkers of DNL.
Abstract:
The present invention provides methods and compositions for treating a subject afflicted with chronic obstructive pulmonary disease (COPD) which comprise a i) a Liver X receptor (LXR) agonist, ii) a miR-33 antagonist, or iii) a TLR4/Myd88 pathway antagonist. The present invention also provides methods and compositions for use in prophylactically treating a subject for chronic obstructive pulmonary disease (COPD) which comprise i) a Liver X receptor (LXR) agonist, ii) a miR-33 antagonist, or iii) a TLR4/Myd88 pathway antagonist.
Abstract:
The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or TRIM proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions.
Abstract:
Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors haveexploredthe metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-HODE as biomarker.
Abstract:
The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.